title: Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders.
abstract: Chronic hepatitis C virus (HCV) infection causes significant mortality in patients with inherited bleeding disorders, however, data of interferon-free antiviral regimes are scarce in this population.
  
  
  METHODS
  Real-life data of interferon-free therapies of 18 patients with inherited bleeding disorders and chronic HCV genotype 1 infection (94% male, liver cirrhosis Child A/B n = 4/1).
  
  
  RESULTS
  Treatment naïve patients were treated for eight weeks with sofosbuvir (SOF)/ledipasvir (n = 3) or for 12 weeks with SOF/ledipasvir (n = 4), SOF/ledipasvir/ribavirin (n = 1), or paritaprevir/r, ombitasvir, dasabuvir (n = 1). Treatment experienced patients without cirrhosis received SOF/ledipasvir (n = 3) or paritaprevir/r, ombitasvir, dasabuvir ± ribavirin (n = 2) for 12 weeks. Re-treated cirrhotic individuals were treated for 24 weeks with SOF/ledipasvir (n = 2) and SOF/daclatasvir (n = 1), or for 12 weeks SOF/simeprevir/1200 mg/d ribavirin (n = 1). Sustained virologic response (SVR-12) was achieved by 17/18 individuals without severe on-treatment side effects.
  
  
  CONCLUSIONS
  In real-life, HCV-infected patients with inherited bleeding disorders can be effectively and safely treated with interferon-free therapies.
authors.affiliation: Johannes Wiegand, University of Leipzig, Department of Internal Medicine, Dermatology, and Neurology, Clinic of Gastroenterology and Rheumatology, Section of Hepatology, Liebigstr. 20, 04103 Leipzig, Germany, Tel. +49/(0)341/971 23-30, Fax -39, E-mail: johannes.wiegand@medizin.uni-leipzig.de.
authors.forename: Johannes
authors.initials: J
authors.lastname: Wiegand
authors.forename: Ingolf
authors.initials: I
authors.lastname: Schiefke
authors.forename: Kerstin
authors.initials: K
authors.lastname: Stein
authors.forename: Thomas
authors.initials: T
authors.lastname: Berg
authors.forename: Ulrike
authors.initials: U
authors.lastname: Kullig
authors.forename: Katrin
authors.initials: K
authors.lastname: Ende
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D025861:Blood Coagulation Disorders, Inherited / Q000150:complications* / Q000175:diagnosis; D005260:Female; D006470:Hemorrhage / Q000150:complications* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069474:Sofosbuvir / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007372:Interferons; D000069474:Sofosbuvir
keywords: Sofosbuvir; daclatasvir; ledipasvir; paritaprevir; simeprevir